Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform

July 22, 2019 8:00 AM

Innovative XCART technology platform designed to target personalized, patient-specific tumor neoantigens has the potential to transform CAR T cell therapy XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non-Hodgkin Lymphoma of over $5 billion annually FRAMINGHAM, MA / ACCESSWIRE / July 22, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO)...

Read more

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present New 90 Day VenoValve Data at the Second Annual Society of Vascular and Endovascular Surgery Congress of Central America and the Caribbean On July 25, 2019

July 19, 2019 8:31 AM

Management to Host VenoValve Webcast and Conference Call on July 25, 2019 at 11:00 am Eastern Time IRVINE, CA / ACCESSWIRE / July 19, 2019 / Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Thursday, July 25, 2019, Dr. Jorge Hernando Ulloa, Principal Investigator for HJLI’s first-in-man VenoValve study in Bogota, Colombia, will present new 90...

Read more

Pressure BioSciences' PCT Platform Highlighted at International Conference in China

July 18, 2019 9:29 AM

Scientists from the Elite Westlake University Report on the Use of the PCT Platform to Significantly Improve the Preparation of Clinical Laboratory Specimens for Evaluation SOUTH EASTON, MA / ACCESSWIRE / July 18, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments and related consumables for the worldwide life sciences and...

Read more

AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock

July 17, 2019 11:35 PM

BROOKLYN, NY / ACCESSWIRE / July 17, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the pricing of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1.00 per share. AzurRx expects to receive aggregate gross proceeds of $5.0 million from the offering. The offering is expected to close on or about July 22, 2019, subject to customary...

Read more

Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

July 17, 2019 8:45 AM

FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced the pricing of an underwritten public offering of 2,300,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof)...

Read more

HemaGenetics Announces Upcoming Annual General & Special Meeting of Shareholders, and Entry Into Arrangement Agreement

July 9, 2019 3:10 PM

VANCOUVER, BC / ACCESSWIRE / July 9, 2019 / HemaGenetics Technologies Corp. (the “Company”) is pleased to announce that it will be holding its annual general & special meeting of its shareholders on August 9, 2019 at 10 a.m. at Suite 300 - 1055 W. Hastings St., Vancouver, BC, Canada, V6E 2E9 (the “Meeting”). Shareholders of record as of July 12, 2019 will be entitled to vote at the Meeting. The purpose of the Meeting will be for shareholders to...

Read more

HemaGenetics Technologies Announces Appointment To Its Board of Directors

July 5, 2019 1:50 PM

VANCOUVER, BC / ACCESSWIRE / July 5, 2019 / HemaGenetics Technologies Corp. (the “Company” or “HTC”) is pleased to announce the appointment of Richard Paolone as a director of HTC effective immediately.Bio of appointeeRichard Paolone - holds a Juris Doctorate and Bachelor of Arts degree. Mr. Paolone is currently employed at a boutique securities law firm that is focused on corporate finance and M&A in Toronto, Ontario. He has experience in the...

Read more

Dyadic Extends Research and Development Agreement with VTT

July 5, 2019 8:30 AM

JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre of Finland Ltd. ("VTT"), a world leading synthetic biology research and development organization.Under the terms of this extended multi-year...

Read more

Dyadic Joins Russell Microcap(R) Index

July 2, 2019 8:40 AM

JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, announced today that the Company was added to the...

Read more

Dyadic Announces Appointment of Ping Rawson to CFO

June 27, 2019 9:23 AM

JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, today announced the appointment of Ping Rawson to Chief Financial...

Read more

Pressure BioSciences Enters CBD Market with Launch of Novel Instrument System to Revolutionize Manufacturing of High Quality, Water-Soluble CBD

June 27, 2019 9:05 AM

Purchase Deposits for the New BaroShear K45 System Will be Accepted Immediately; Company Believes Sales into the CBD Market Could Double Current Revenue by Q2 2020 SOUTH EASTON, MA / ACCESSWIRE / June 27, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences...

Read more

Hancock Jaffe Reports Early Positive Results For CoreoGraft Animal Feasibility Study

June 27, 2019 8:30 AM

No Device Failures in Eight Test Subjects IRVINE, CA / ACCESSWIRE / June 27, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today provided an update on the status of its CoreoGraft animal feasibility study. There have been no device failures in eight animal test subjects where CoreoGrafts have been implanted as heart bypass grafts, with one group observed...

Read more

Pressure BioSciences Announces Achievement of First Major Milestone in Development of Potential Breakthrough Processing Method for Higher Quality and Safer Food and Beverages

June 26, 2019 9:05 AM

Proprietary, Custom Built UST-Based Instrument Delivered to Collaborators at The Ohio State University; OSU Scientists to Study Pressure and Shear Effects on Pathogen Inactivation, Stability, and Quality SOUTH EASTON, MA / ACCESSWIRE / June 26, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences...

Read more

Primary Investigator Dr. Jorge Hernando Ulloa Reports New and Updated VenoValve Data at C3 Global Conference

June 24, 2019 11:00 AM

Clinical Manifestations of CVI Improved an Average of 46% Across All Five VenoValve Patients IRVINE, CA / ACCESSWIRE / June 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Sunday, June 23, 2019, Dr. Jorge Hernando Ulloa, the Primary Investigator for HJLI's first-in-human VenoValve study in Bogota, Colombia, reported new and updated...

Read more

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

June 24, 2019 9:08 AM

FRAMINGHAM, MA / ACCESSWIRE / June 24, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), today announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the...

Read more

Hemogenyx Pharmaceuticals PLC Announces Development of ApbHC

June 24, 2019 2:00 AM

Development of ApbHC, a Novel Type of Humanized Mouse LONDON / ACCESSWIRE / June 24, 2019 / Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that its wholly owned subsidiary Immugenyx, LLC ("Immugenyx") has developed an Advanced peripheral blood Hematopoietic Chimera ("ApbHC"), a novel type of humanized mouse that presents several advantages over other mouse models. Immugenyx was established by the Company to develop and commercialise the...

Read more

Experion’s Brand, Kanabé Goods Co., Well Positioned to Take Advantage of New Health Canada Regulations

June 21, 2019 8:30 AM

VANCOUVER, BC / ACCESSWIRE / June 21, 2019 / Experion Holdings Ltd. ("Experion" or the "Company") (TSXV: EXP) (OTCQB:EXPFF), formerly Viridium Pacific Group Ltd., is pleased to provide an update on the Company's brands positioned to take advantage of Health Canada's final regulations for Value-Add Products (VAP's) such as cannabis topicals, edibles and extracts as well as Health Canada's proposal to create a new category ''Cannabis Health...

Read more

Hancock Jaffe Hires Brian Roselauf as Director of Research and Development

June 20, 2019 8:31 AM

IRVINE, CA / ACCESSWIRE / June 20, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, today announced that Brian Roselauf will be joining the company as its Director of Research and Development. Mr. Roselauf will join Hancock Jaffe on June 24, 2019, and will initially focus on design verification and validation activities to prepare for the filing of the...

Read more

Hancock Jaffe Primary Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Report at the Venous Summit at the C3 Global Conference

June 19, 2019 1:30 PM

VenoValve Presentation on June 23, 2019 in Orlando, Florida IRVINE, CA / ACCESSWIRE / June 19, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, HJLI's Primary Investigator for its first-in-human VenoValve study in Bogota, Colombia, will report on initial VenoValve data at the 2019 Venous Summit at the 15th annual...

Read more

Pressure BioSciences' Ultra High Pressure HUB Platform Highly Effective in Studies to Develop Improved Methods for Food Safety

June 19, 2019 9:32 AM

HUB Platform Plays Critical Role in Innovative Research Studies Designed to Increase Understanding of and Develop Methods for the Prevention of Serious Food-Borne Diseases Caused by E. coli and Listeria SOUTH EASTON, MA / ACCESSWIRE / June 19, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology...

Read more